HPR171 Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers
Abstract
Authors
Stefan Walzer Lutz Michael Vollmer Dingeman Wolfert Anne M. Loos Eddie Gibson